Zynerba Pharmaceuticals, Inc. (ZYNE) Financials

NASDAQ Currency in USD Disclaimer

$1.30

north_east NA Past Year
Day's range
$1.26
Day's range
$1.34
$10M$10M$0$0-$10M-$10M-$20M-$20M-$30M-$30M-$40M-$40M-$50M-$50M-$60M-$60MEarning201620162017201720182018201920192020202020212021202220220%0%-100000%-100000%-200000%-200000%-300000%-300000%-400000%-400000%-500000%-500000%-600000%-600000%-700000%-700000%Profit Margin
Profit Margin
Revenue
Earnings

ZYNE Income statement / Annual

Last year (2022), Zynerba Pharmaceuticals, Inc.'s total revenue was $0.00, and the percentage change from the previous year is not available. In 2022, Zynerba Pharmaceuticals, Inc.'s net income was -$34.82 M. See Zynerba Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014 FY-2013
Period Ended 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Operating Revenue $0.00 $0.00 $0.00 $0.00 $86,000.00 $7,250.00 $7,250.00 $278,900.00 $810,012.00 $943,904.00
Cost of Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00 $86,000.00 $7,250.00 $7,250.00 $278,900.00 $810,012.00 $943,904.00
Gross Profit Ratio 0 0 0 0 1 1 1 1 1 1
Research and Development Expenses $21.10 M $21.42 M $35.65 M $20.38 M $27.25 M $22.81 M $16.78 M $7.45 M $2.40 M $1.13 M
General & Administrative Expenses $14.15 M $15.35 M $16.41 M $13.94 M $13.24 M $10.02 M $6.43 M $5.36 M $4.08 M $444,302.00
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $14.15 M $15.35 M $16.41 M $13.94 M $13.24 M $10.02 M $6.43 M $5.36 M $4.08 M $444,302.00
Other Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expenses $35.25 M $36.77 M $52.06 M $34.32 M $40.48 M $32.82 M $23.21 M $12.81 M $6.48 M $1.58 M
Cost And Expenses $35.25 M $36.77 M $52.06 M $34.32 M $40.48 M $32.82 M $23.21 M $12.81 M $6.48 M $1.58 M
Interest Income $846,860.00 $21,047.00 $243,992.00 $1.52 M $961,323.00 $519,554.00 $80,222.00 $0.00 $0.00 $0.00
Interest Expense -$215,734.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $631,126.00 $559,681.00 -$481,719.00 $145,911.00 $99,572.00 $94,211.00 $75,301.00 $26,027.00 $27,063.00 $49,392.00
EBITDA -$34.62 M -$36.21 M -$52.06 M -$34.17 M -$40.40 M -$32.82 M -$23.21 M -$12.51 M -$5.64 M -$585,047.00
EBITDA Ratio 0 0 0 0 -464.22 -4567.47 -3161.24 -44.84 -6.96 -0.62
Operating Income Ratio 0 0 0 0 -469.74 -4527.31 -3201.05 -44.93 -7 -0.67
Total Other Income/Expenses Net $215,734.00 -$538,634.00 $725,711.00 $1.38 M $486,655.00 $810,705.00 -$208,422.00 $7,352.00 -$1,844.00 -$2,351.00
Income Before Tax -$35.04 M -$37.31 M -$51.34 M -$32.94 M -$39.91 M -$32.01 M -$23.42 M -$12.52 M -$5.67 M -$636,790.00
Income Before Tax Ratio 0 0 0 0 -464.08 -4415.49 -3229.8 -44.9 -7 -0.67
Income Tax Expense -$215,734.00 $291,494.00 -$932,746.00 -$1.51 M $486,655.00 -$27,543.00 -$27,543.00 $27,543.00 $0.00 $0.00
Net Income -$34.82 M -$37.60 M -$50.40 M -$31.43 M -$39.91 M -$32.01 M -$23.39 M -$12.55 M -$5.67 M -$636,790.00
Net Income Ratio 0 0 0 0 -464.08 -4415.49 -3226 -45 -7 -0.67
EPS -0.82 -0.96 -1.87 -1.43 -2.61 -2.48 -2.58 -2.82 -0.99 -0.11
EPS Diluted -0.82 -0.96 -1.87 -1.43 -2.61 -2.48 -2.58 -2.82 -0.99 -0.11
Weighted Average Shares Out $42.66 M $39.26 M $27.02 M $22.00 M $15.31 M $12.91 M $9.07 M $4.46 M $5.73 M $5.73 M
Weighted Average Shares Out Diluted $42.66 M $39.26 M $27.02 M $22.00 M $15.31 M $12.91 M $9.07 M $4.46 M $5.73 M $5.73 M
Link